Our treatments are administered by medical professionals and include an Oligoscan analysis for a comprehensive body composition investigation or a skin analysis to better understand your skin's needs
The combination of a BET inhibitor (+)-JQ-1 and a proteasome inhibitor bortezomib (BTZ) has been shown to decrease GPX4 expression, thereby inducing ferroptosis in TNBC [18]
Subcutaneous injection protocol: Starting dose: 200 to 300 mcg daily Titration: Increase by approximately 100 mcg every 1 to 2 weeks as tolerated Target dose: 400 to 500 mcg daily by weeks 5 through 12 Frequency: Once daily, subcutaneous Cycle length: 8 to 12 weeks, with optional extension to 16 weeks Timing: Consistent daily timing, typically evening for sleep applications Oral/sublingual protocol: Duration: 30 days Frequency: 1 to 4 cycles per year Best combined with: Exercise and nutrient-rich diet Injection sites should be rotated between the abdomen, thighs, and upper arms to prevent lipohypertrophy and ensure consistent absorption
Unraveling the interplay between iron homeostasis, ferroptosis and extramedullary hematopoiesis
Over-the-counter lidocaine cream (4-5%) applied to the injection site 30-60 minutes before injection effectively numbs the skin
GPxs are a family of enzymes homologous to the selenocysteine (Sec)-containing mammalian GPx-1 that uses GSH as an obligate cosubstrate in the reduction of hydrogen peroxide to water